AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 18752983 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study 17004124 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose pegylated interferon alpha-2b plus ribavirin
Number of subjects: 152
Study 17004124 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose pegylated interferon alpha-2b plus ribavirin
Number of subjects: 152
Study 17004124 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 152
Study 15266728 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmaceutical company advertisements
Number of subjects: 44
Study 15266728 — intervention group
Group type: COMPARATOR
Intervention: Scientific information about depression and its treatment
Number of subjects: 44
Study 11350400 — intervention group
Group type: EXPERIMENTAL
Intervention: Symptomatic bladder (P2X1/calponin ratio)
Number of subjects: 9
Study 11350400 — intervention group
Group type: EXPERIMENTAL
Intervention: Symptomatic bladder (P2X4, P2X5, P2X7 expression)
Number of subjects: 9
Study 11350400 — intervention group
Group type: COMPARATOR
Intervention: Control bladder (P2X expression levels)
Number of subjects: 9
Study 9212966 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparin-bonded partial cardiopulmonary bypass with nafamostat mesilate
Number of subjects: 23
Study 9212966 — intervention group
Group type: COMPARATOR
Intervention: Conventional partial cardiopulmonary bypass
Number of subjects: 23
Study 8428872 — intervention group
Group type: EXPERIMENTAL
Intervention: Desipramine (DMI) at daily doses averaging 4 to 5 mg/kg
Number of subjects: 0
Study 8428872 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 8428872 — intervention group
Group type: EXPERIMENTAL
Intervention: Desipramine (DMI)
Number of subjects: 0
Study 3619742 — intervention group
Group type: EXPERIMENTAL
Intervention: Panretinal laser photocoagulation
Number of subjects: 72
Study 3619742 — intervention group
Group type: COMPARATOR
Intervention: Control (untreated eyes)
Number of subjects: 72
Study 3619742 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetic patients (general)
Number of subjects: 72
Study 3619742 — intervention group
Group type: EXPERIMENTAL
Intervention: 30-Hz flicker (in diabetic patients)
Number of subjects: 72
Study 3619742 — intervention group
Group type: COMPARATOR
Intervention: Control subjects
Number of subjects: 72
Study 28921839 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative chemotherapy
Number of subjects: 79
Study 27074775 — intervention group
Group type: EXPERIMENTAL
Intervention: QRS duration >120 milliseconds in AF
Number of subjects: 5436
Study 27074775 — intervention group
Group type: EXPERIMENTAL
Intervention: QRS duration >120 milliseconds in sinus rhythm
Number of subjects: 5436
Study 27074775 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased PR interval (>200 milliseconds)
Number of subjects: 5436
Study 24948414 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% NaHCO3 solution at 45‐50°C
Number of subjects: 120
Study 24948414 — intervention group
Group type: COMPARATOR
Intervention: Talcum powder
Number of subjects: 120
Study 23710789 — intervention group
Group type: EXPERIMENTAL
Intervention: Single interrupted sutures
Number of subjects: 89
Study 23710789 — intervention group
Group type: COMPARATOR
Intervention: Donati sutures
Number of subjects: 89
Study 19717156 — intervention group
Group type: EXPERIMENTAL
Intervention: Perindopril
Number of subjects: 17
Study 19717156 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study 18400702 — intervention group
Group type: EXPERIMENTAL
Intervention: High-carbohydrate diet (10% fat; 75% carbohydrates)
Number of subjects: 8
Study 18400702 — intervention group
Group type: COMPARATOR
Intervention: Higher fat diet (40% fat; 45% carbohydrates)
Number of subjects: 8
Study 17427429 — intervention group
Group type: EXPERIMENTAL
Intervention: Soya-based food
Number of subjects: 0
Study 14607965 — intervention group
Group type: EXPERIMENTAL
Intervention: Dengue virus infection
Number of subjects: 0
Study 14607965 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderately ill children with dengue fever
Number of subjects: 0
Study 14607965 — intervention group
Group type: EXPERIMENTAL
Intervention: Children who subsequently developed dengue hemorrhagic fever
Number of subjects: 0
Study 14607965 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls and mild other nondengue febrile illness
Number of subjects: 0
Study 11004053 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral nifedipine (60 mg)
Number of subjects: 92
Study 11004053 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous nimodipine (30 microg x kg(‐1) x h(‐1) over 20 h)
Number of subjects: 92
Study 11004053 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous magnesium sulfate (initial dose of 30 mg/kg followed by 10 mg x kg(‐1) x h(‐1) over 20 h)
Number of subjects: 92
Study 11004053 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 92
Study 8945030 — intervention group
Group type: EXPERIMENTAL
Intervention: Medtronic Thera DR pacemaker with automatic mode switching (AMS) algorithm
Number of subjects: 26
Study 8945030 — intervention group
Group type: EXPERIMENTAL
Intervention: Medtronic Thera DR pacemaker with AMS
Number of subjects: 26
Study 1754849 — intervention group
Group type: EXPERIMENTAL
Intervention: Nocloprost 200 micrograms
Number of subjects: 0
Study 1754849 — intervention group
Group type: EXPERIMENTAL
Intervention: Nocloprost 100 micrograms three times daily
Number of subjects: 0
Study 1754849 — intervention group
Group type: EXPERIMENTAL
Intervention: Nocloprost 50-100 micrograms
Number of subjects: 0
Study 503763 — intervention group
Group type: EXPERIMENTAL
Intervention: Familiar music (rock and easy-listening)
Number of subjects: 35
Study 503763 — intervention group
Group type: EXPERIMENTAL
Intervention: Unfamiliar music (rock and easy-listening)
Number of subjects: 35
Study 503763 — intervention group
Group type: COMPARATOR
Intervention: No music
Number of subjects: 35
Study 31935118 — intervention group
Group type: EXPERIMENTAL
Intervention: Omega-3 fatty acids (4 capsules, 2.4 g daily for 12 weeks)
Number of subjects: 93
Study 31935118 — intervention group
Group type: COMPARATOR
Intervention: Paraffin oil (control group)
Number of subjects: 93
Study 31605466 — intervention group
Group type: EXPERIMENTAL
Intervention: Weighted genetic risk score (GRS)
Number of subjects: 13945
Study 27538739 — intervention group
Group type: EXPERIMENTAL
Intervention: Incremental technique with conventional flowable composite (Aelite Flo)
Number of subjects: 37
Study 27538739 — intervention group
Group type: EXPERIMENTAL
Intervention: Bulk-filling technique with bulk-fill flowable composite (x-tra base)
Number of subjects: 37
Study 27538739 — intervention group
Group type: COMPARATOR
Intervention: Comparison between incremental technique and bulk-filling technique
Number of subjects: 37
Study 26036592 — intervention group
Group type: EXPERIMENTAL
Intervention: Tacrolimus (TAC), n=29
Number of subjects: 133
Study 26036592 — intervention group
Group type: COMPARATOR
Intervention: Control group, n=35
Number of subjects: 133
Study 26036592 — intervention group
Group type: EXPERIMENTAL
Intervention: Methotrexate (MTX), n=55
Number of subjects: 133
Study 26036592 — intervention group
Group type: EXPERIMENTAL
Intervention: TAC/MTX, n=14
Number of subjects: 133
Study 23994918 — intervention group
Group type: EXPERIMENTAL
Intervention: Cytoflavin (20‐40 ml daily intravenously in drops for 10 days)
Number of subjects: 191
Study 23994918 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment only
Number of subjects: 191
Study 22290679 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexketoprofen 25 mg (Group D)
Number of subjects: 75
Study 22290679 — intervention group
Group type: EXPERIMENTAL
Intervention: Paracetamol 500 mg (Group P)
Number of subjects: 75
Study 22290679 — intervention group
Group type: COMPARATOR
Intervention: Placebo (Group C)
Number of subjects: 75
Study 19803237 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroacupuncture at local points combined with blood‐letting puncture and cupping (on the basis of diet intervention)
Number of subjects: 60
Study 19803237 — intervention group
Group type: COMPARATOR
Intervention: Oral administration of Probenecid (on the basis of diet intervention)
Number of subjects: 60
Study 19803237 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (Electroacupuncture plus blood-letting puncture and cupping and Probenecid)
Number of subjects: 60
Study 16891570 — intervention group
Group type: EXPERIMENTAL
Intervention: Paroxetine treatment for 12 months
Number of subjects: 13
Study 16012271 — intervention group
Group type: EXPERIMENTAL
Intervention: Ziprasidone (40 to 80 mg BID)
Number of subjects: 202
Study 16012271 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 202
Study 16012271 — intervention group
Group type: EXPERIMENTAL
Intervention: Ziprasidone
Number of subjects: 202
Study 12602375 — intervention group
Group type: EXPERIMENTAL
Intervention: Darbepoetin alfa
Number of subjects: 0
Study 12602375 — intervention group
Group type: COMPARATOR
Intervention: Epoetin alfa and beta
Number of subjects: 0
Study 9856370 — intervention group
Group type: EXPERIMENTAL
Intervention: Lisinopril at 20 mg with the addition of 12.5 or 25 mg hydrochlorothiazide as needed
Number of subjects: 174
Study 9856370 — intervention group
Group type: COMPARATOR
Intervention: Placebo (during final study month)
Number of subjects: 174
Study 7619769 — intervention group
Group type: EXPERIMENTAL
Intervention: Trilostane
Number of subjects: 112
Study 7619769 — intervention group
Group type: EXPERIMENTAL
Intervention: Aminoglutethimide
Number of subjects: 112
Study 7619769 — intervention group
Group type: EXPERIMENTAL
Intervention: Both drugs
Number of subjects: 112
Study 2797545 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoride rinse (0.2 percent sodium fluoride solution)
Number of subjects: 273
Study 2797545 — intervention group
Group type: COMPARATOR
Intervention: Placebo rinse
Number of subjects: 273
Study 344898 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of cyclophosphamide, methotrexate, 5‐fluorouracil, vincristine, and prednisone (repeated weekly treatment)
Number of subjects: 281
Study 344898 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent treatment of the same five drugs given in 5‐day courses every 4 weeks
Number of subjects: 281
Study 344898 — intervention group
Group type: EXPERIMENTAL
Intervention: Adriamycin as a single agent (treatment every 3 weeks)
Number of subjects: 281
Study 344898 — intervention group
Group type: COMPARATOR
Intervention: Non-Caucasian patients
Number of subjects: 281
Study 344898 — intervention group
Group type: COMPARATOR
Intervention: Caucasian patients
Number of subjects: 281
Study 344898 — intervention group
Group type: EXPERIMENTAL
Intervention: Ambulatory patients with long disease-free intervals and no liver involvement
Number of subjects: 281
Study 344898 — intervention group
Group type: EXPERIMENTAL
Intervention: Remaining covariates (menopausal status, bone involvement, number of metastatic sites, duration of metastatic disease)
Number of subjects: 281
Study 344898 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment effect
Number of subjects: 281
Study 29935152 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive training program (n=51)
Number of subjects: 104
Study 29935152 — intervention group
Group type: COMPARATOR
Intervention: Self-directed program (n=53)
Number of subjects: 104
Study 28504067 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual therapy and exercise plus TrP dry needling (DN)
Number of subjects: 60
Study 28504067 — intervention group
Group type: COMPARATOR
Intervention: Manual therapy and exercises
Number of subjects: 60
Study 26126684 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute exercise (1.5 h at 50% V̇o2 max)
Number of subjects: 3
Study 26126684 — intervention group
Group type: EXPERIMENTAL
Intervention: Subset of sphingomyelin species (C14:0, C22:3, C24:4)
Number of subjects: 3
Study 26126684 — intervention group
Group type: COMPARATOR
Intervention: Basal serum levels
Number of subjects: 3
Study 23776118 — intervention group
Group type: EXPERIMENTAL
Intervention: Darbepoetin alfa (Darbe) 10 μg/kg, 1 time per week subcutaneously
Number of subjects: 102
Study 23776118 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythropoietin (Epo) 400 U/kg, 3 times per week subcutaneously
Number of subjects: 102
Study 23776118 — intervention group
Group type: COMPARATOR
Intervention: Placebo (sham dosing)
Number of subjects: 102
Study 20929555 — intervention group
Group type: EXPERIMENTAL
Intervention: Usual care + brief 2-session psychological intervention
Number of subjects: 60
Study 20929555 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 60
Study 19036233 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg/day of quetiapine fumarate
Number of subjects: 141
Study 19036233 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 mg/day of quetiapine fumarate
Number of subjects: 141
Study 19036233 — intervention group
Group type: EXPERIMENTAL
Intervention: Flexible dosing in Part 2
Number of subjects: 141
Study 15737443 — intervention group
Group type: EXPERIMENTAL
Intervention: Gravity inversion position
Number of subjects: 22
Study 15737443 — intervention group
Group type: COMPARATOR
Intervention: Chronic low-back pain group
Number of subjects: 22
Study 12975010 — intervention group
Group type: EXPERIMENTAL
Intervention: Agrippal
Number of subjects: 499
Study 12975010 — intervention group
Group type: COMPARATOR
Intervention: Flurix
Number of subjects: 499
Study 10534145 — intervention group
Group type: EXPERIMENTAL
Intervention: Didanosine and stavudine (100 + 10 mg, 100 + 20 mg, 100 + 40 mg, 200 + 20 mg, and 200 + 40 mg)
Number of subjects: 86
Study 10534145 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose subgroup (arms 3, 4, and 5)
Number of subjects: 86
Study 10534145 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy (didanosine and stavudine)
Number of subjects: 86
Study 8762780 — intervention group
Group type: EXPERIMENTAL
Intervention: Keeler Pulsair 2000
Number of subjects: 45
Study 8762780 — intervention group
Group type: EXPERIMENTAL
Intervention: American Optical MkII
Number of subjects: 45
Study 8762780 — intervention group
Group type: COMPARATOR
Intervention: Goldmann applanation tonometer
Number of subjects: 45
Study 1817622 — intervention group
Group type: EXPERIMENTAL
Intervention: Verapamil 0.01 mg kg‐1 h‐1 (n = 12)
Number of subjects: 25
Study 1817622 — intervention group
Group type: COMPARATOR
Intervention: Saline (n = 13)
Number of subjects: 25
Study 6983207 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultraviolet radiation (UVR) once a week for three months
Number of subjects: 42
Study 6983207 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral vitamin D2 (450 IU) with 420 mg calcium daily
Number of subjects: 42
Study 6983207 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium alone (420 mg)
Number of subjects: 42
Study 6983207 — intervention group
Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 42
Study 30597503 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjusted dose of enoxaparin according to anti-factor Xa levels
Number of subjects: 88
Study 30597503 — intervention group
Group type: COMPARATOR
Intervention: Fixed dose of 40 mg daily LMWH
Number of subjects: 88
Study 29018949 — intervention group
Group type: EXPERIMENTAL
Intervention: Metronome-paced strength training (MPST)
Number of subjects: 44
Study 29018949 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-paced strength training (SPST)
Number of subjects: 44
Study 29018949 — intervention group
Group type: EXPERIMENTAL
Intervention: Skill training
Number of subjects: 44
Study 29018949 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 44
Study 26445532 — intervention group
Group type: EXPERIMENTAL
Intervention: 250 mg Polygonum minus extract (PM) taken twice daily for 6 weeks
Number of subjects: 35
Study 24268874 — intervention group
Group type: EXPERIMENTAL
Intervention: Isometric training
Number of subjects: 36
Study 24268874 — intervention group
Group type: EXPERIMENTAL
Intervention: Isotonic training
Number of subjects: 36
Study 24268874 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 36
Study 22425113 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment with sham escalation
Number of subjects: 435
Study 22425113 — intervention group
Group type: COMPARATOR
Intervention: Placebo escalators
Number of subjects: 435
Study 22425113 — intervention group
Group type: COMPARATOR
Intervention: Placebo nonescalators
Number of subjects: 435
Study 22425113 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 435
Study 19092364 — intervention group
Group type: EXPERIMENTAL
Intervention: Cytokine therapy (granulocyte colony-stimulating factor, erythropoietin, and stem cell factor)
Number of subjects: 0
Study 19092364 — intervention group
Group type: EXPERIMENTAL
Intervention: Cytokine therapy alone
Number of subjects: 0
Study 19092364 — intervention group
Group type: EXPERIMENTAL
Intervention: Various combinations of cytokines with or without stem cell therapy
Number of subjects: 0
Study 17297068 — intervention group
Group type: EXPERIMENTAL
Intervention: Training + Incentive (TI)
Number of subjects: 577
Study 17297068 — intervention group
Group type: EXPERIMENTAL
Intervention: Training + Medication (TM)
Number of subjects: 577
Study 17297068 — intervention group
Group type: EXPERIMENTAL
Intervention: Training + Incentive + Medication (TI+TM)
Number of subjects: 577
Study 17297068 — intervention group
Group type: COMPARATOR
Intervention: Usual Care (Control)
Number of subjects: 577
Study 15596181 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamsulosin 0.4 mg daily
Number of subjects: 78
Study 15596181 — intervention group
Group type: COMPARATOR
Intervention: Standard hydration and diclofenac sodium
Number of subjects: 78
Study 11080399 — intervention group
Group type: EXPERIMENTAL
Intervention: Hand-assisted laparoscopic surgery (HALS)
Number of subjects: 40
Study 11080399 — intervention group
Group type: COMPARATOR
Intervention: Standard laparoscopic surgery (SLS)
Number of subjects: 40
Study 9058557 — intervention group
Group type: EXPERIMENTAL
Intervention: Supportive-expressive (SE) therapy
Number of subjects: 32
Study 9058557 — intervention group
Group type: COMPARATOR
Intervention: Cognitive therapy (CT)
Number of subjects: 32
Study 9058557 — intervention group
Group type: COMPARATOR
Intervention: Individual drug counseling (IDC)
Number of subjects: 32
Study 8354729 — intervention group
Group type: EXPERIMENTAL
Intervention: ePTFE plus DFDBA (experimental)
Number of subjects: 15
Study 8354729 — intervention group
Group type: COMPARATOR
Intervention: DFDBA alone (control)
Number of subjects: 15
Study 3731684 — intervention group
Group type: EXPERIMENTAL
Intervention: prazosin (1 mg t.i.d.)
Number of subjects: 24
Study 3731684 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 24
Study 31391133 — intervention group
Group type: EXPERIMENTAL
Intervention: e‐health program providing diet, physical activity and well‐being advice over 12 weeks
Number of subjects: 57
Study 31391133 — intervention group
Group type: COMPARATOR
Intervention: Routine antenatal care
Number of subjects: 57
Study 30428513 — intervention group
Group type: EXPERIMENTAL
Intervention: Tabby Improved Prevention and Intervention Program (TIPIP)
Number of subjects: 759
Study 30428513 — intervention group
Group type: COMPARATOR
Intervention: Control Group
Number of subjects: 759
Study 26999688 — intervention group
Group type: EXPERIMENTAL
Intervention: Antioxidants (1 gram L-ascorbic acid per day)
Number of subjects: 200
Study 26999688 — intervention group
Group type: EXPERIMENTAL
Intervention: Antioxidants
Number of subjects: 200
Study 25128278 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapid Palatal Expansion (RPE)
Number of subjects: 20
Study 25128278 — intervention group
Group type: COMPARATOR
Intervention: Slow Palatal Expansion (SPE)
Number of subjects: 20
Study 25128278 — intervention group
Group type: EXPERIMENTAL
Intervention: Both RPE and SPE
Number of subjects: 20
Study 22921557 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based cyclergometer training (30 min/day for 3 months, with monthly-supervised sessions)
Number of subjects: 23
Study 22921557 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 23
Study 20368021 — intervention group
Group type: EXPERIMENTAL
Intervention: Early air drainage (< 72 h)
Number of subjects: 242
Study 20368021 — intervention group
Group type: COMPARATOR
Intervention: Delayed air drainage (> 6 d)
Number of subjects: 242
Study 18711762 — intervention group
Group type: EXPERIMENTAL
Intervention: Tai Ji Quan (TJQ) exercise, 1 hour per day, 5 days a week for 14 weeks
Number of subjects: 20
Study 18711762 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 20
Study 16400783 — intervention group
Group type: EXPERIMENTAL
Intervention: Balance training (BT)
Number of subjects: 42
Study 16400783 — intervention group
Group type: EXPERIMENTAL
Intervention: Isometric training (IT)
Number of subjects: 42
Study 16400783 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 42
Study 12914389 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant chemoradiation
Number of subjects: 0
Study 12914389 — intervention group
Group type: COMPARATOR
Intervention: Resected patients
Number of subjects: 0
Study 10102949 — intervention group
Group type: EXPERIMENTAL
Intervention: Plain aspirin 300 mg
Number of subjects: 12
Study 10102949 — intervention group
Group type: EXPERIMENTAL
Intervention: Plain aspirin 75 mg
Number of subjects: 12
Study 10102949 — intervention group
Group type: EXPERIMENTAL
Intervention: Enteric-coated aspirin 300 mg
Number of subjects: 12
Study 10102949 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 7484589 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative MR imaging at 1.5 T
Number of subjects: 25
Study 7484589 — intervention group
Group type: COMPARATOR
Intervention: Clinical criteria for biopsy site selection (no MR imaging)
Number of subjects: 25
Study 2138163 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous suture + suction drain
Number of subjects: 93
Study 2138163 — intervention group
Group type: COMPARATOR
Intervention: Simple suture at wide intervals of 4 cm
Number of subjects: 93
Study 7432659 — intervention group
Group type: EXPERIMENTAL
Intervention: Alpha-mercaptopropionylglycine (1500 mg/day per os)
Number of subjects: 40
Study 7432659 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 30224383 — intervention group
Group type: EXPERIMENTAL
Intervention: CNP520
Number of subjects: 0
Study 27234460 — intervention group
Group type: EXPERIMENTAL
Intervention: Low polyunsaturated fat intake (1-4 g)
Number of subjects: 1672